Published in final edited form as:

Adv Synth Catal. 2008 August 4; 350(11-12): 1717–1728. doi:10.1002/adsc.200800129.

Chemoenzymatic Syntheses of Tumor-Associated Carbohydrate Antigen Globo-H and Stage-Specific Embryonic Antigen 4

Zhen Wang^a, Michel Gilbert^b, Hironobu Eguchi^c, Hai Yu^d, Jiansong Cheng^d, Saddam Muthana^d, Luyuan Zhou^a, Peng George Wang^c, Xi Chen^d, and Xuefei Huang^{a,*}

^a Department of Chemistry, The University of Toledo, 2801 W. Bancroft Street, MS 602, Toledo, Ohio 43606 USA

^b National Research Council Canada, Institute for Biological Sciences, Glycobiology Program, 100 Sussex Drive, Ottawa, ON K1A 0R6 Canada

^c The Ohio State University, Departments of Biochemistry and Chemistry, 484 West 12th Avenue, Columbus, OH 43210 USA

^d Department of Chemistry, University of California, One Shields Avenue, Davis, CA USA

Abstract

Gangliosides have attracted much attention due to their important biological properties. Herein, we report the first chemoenzymatic syntheses of two globo series of ganglioside oligosaccharides, Globo-H **1** and stage-specific embryonic antigen-4 (SSEA-4) **2**. The common precursor SSEA-3 pentasaccharide for these two compounds was assembled rapidly using the pre-activation based one-pot glycosylation method. The stereoselectivity in forming the 1,2-*cis* linkage in SSEA-3 was attributed to a steric buttressing effect of the donor rather than electronic properties of the glycosyl donors. SSEA-3 was then successfully fucosylated by the fucosyltransferase WbsJ and sialylated by sialyltransferases CST-I and PmST1 producing Globo-H and SSEA-4 respectively.

Keywords

carbohydrates; chemoenzymatic synthesis; natural products; oligosaccharides; stereoselectivity

Introduction

The globo series of gangliosides, including Globo-H **1** and stage-specific embryonic antigen-4 (SSEA-4) **2**, possess the β -GalNAc-(1 $\rightarrow$ 3)- α -Gal-(1 $\rightarrow$ 4)-Gal oligosaccharide moiety.[1,2] This family of glycolipids has attracted much attention due to their roles as tumor-associated antigens[2] and as receptors for bacteria, viruses and toxins, which present excellent targets for novel therapeutics design.[3–5] For example, Globo-H has been found to be over-expressed on a variety of human cancer cells, including breast cancer, prostate cancer, ovarian cancer, and lung carcinomas.[6,7] Immunotherapy using Globo-H hexasaccharide as a cancer vaccine [8] has received encouraging preliminary results against breast cancer, which is now undergoing phase II clinical trial.[9–11] SSEA-4 is believed to be involved in bacterial and viral infections, serving as receptors for uropathogenic *Escherichia coli*[12–14] and human

Fax: (+1) 419-530-4033, Xuefei.huang@utoledo.edu.

Dedicated to Prof. Chi-Huey Wong on the occasion of his 60th birthday for his ground breaking contributions to chemistry.

Supporting information Available: Supporting information for this article is available on the WWW under <http://asc.wiley-vch.de/home/>.

parvovirus B19.[15] In addition, SSEA-4 is a marker for human cancer cells[16–19] and the expression level of SSEA-4 shows clear correlation with metastasis potential and malignancy of renal cell carcinoma.[20–23]

Due to their biological importance and the difficulties in accessing these complex oligosaccharides from natural sources, great efforts have been devoted to chemical synthesis. [1,24] Globo-H hexasaccharide has been assembled by a variety of methods including the glycal strategy,[25] the trichloroacetimidate method,[26] two-directional glycosylation,[27] automated solid phase synthesis,[28] the reactivity based one-pot method[29] as well as the pre-activation based one-pot method.[30] With the presence of the sialic acid unit at its non-reducing end, SSEA-4 presents additional synthetic challenges. Although much progress has been made in chemical sialylation,[31,32] it still remains one of the most difficult glycosidic linkages to synthesize. The carboxylic acid moiety in sialic acid also requires additional consideration for protective group compatibility in synthetic design.[33] To date, SSEA-4 has only been assembled twice by the Hasagawa[34] group and the Schmidt/Garegg group.[35] The successful completion of these highly challenging structures serves as highlights of the power of modern carbohydrate synthetic methodologies. However, despite these accomplishments, there is a continual need to further improve synthetic efficiencies of these molecules.

An attractive alternative to chemical synthesis is enzymatic synthesis.[36,37] With their high regio- and stereo-selectivities, glycosyltransferases can facilitate the formation of glycosidic bonds under aqueous conditions without relying heavily on protective groups. However, enzymatic activities can be highly dependent upon structures of both the glycosyl donor and the acceptor. An effective enzymatic synthesis may require the preparation and screening of an array of enzymes, which can be time consuming. Thus, chemoenzymatic synthesis, through the combination of the power of enzymatic synthesis with the flexibility of chemical synthesis, presents a potent approach to access complex oligosaccharides. Several gangliosides such as GM3,[38] GM2,[39] GM1,[39] GD1a,[39] Gb3[40] and SSEA-3[41] have been synthesized chemoenzymatically. Herein, we report our studies on chemoenzymatic syntheses of Globo-H **1b** and SSEA-4 **2b**, both of which contain aminopropyl side chains and can be conjugated to protein carriers for future immunological studies.

Results and Discussion

Retrosynthetically, we envision that both Globo-H and SSEA-4 can be accessed by enzymatic glycosylation of pentasaccharide SSEA-3 **3**, which is also a tumor associated carbohydrate antigen.[42] The pentasaccharide **3** in turn can be chemically assembled from disaccharide **5**, galactoside **6**, and lactoside **7** (Figure 1). Based on our previous studies,[30] the presence of electron withdrawing benzoyl moieties on the lactoside acceptor drastically reduced the glycosylation yield. Thus, the electron donating benzyl groups are selected as protective groups masking hydroxyl groups not undergoing glycosylation in order to enhance the nucleophilicity of the acceptors as well as to simplify deprotection procedures. A side effect of using benzyl groups is that building block galactoside **6** possesses high anomeric reactivity (armed)[43] as a glycosyl donor with its multiple electron donating protective groups.[36] Therefore, in chemoselective glycosylation of thiogalactoside **6** by the thioglycosyl donor **5**, cautions must be taken to prevent the undesired premature activation of galactoside **6**. This can be achieved by pre-activating[44–48] disaccharide **5** first with a stoichiometric promoter, generating a reactive intermediate. Upon complete donor activation, addition of the bifunctional galactoside **6** building block to the reaction mixture will produce the desired trisaccharide. As donor activation and acceptor addition occur at two distinct steps, even though the acceptor **6** has high anomeric reactivity, it will not be activated by the promoter.

For the pre-activation based glycosylation approach, we have extensively used the *p*-TolSCI/AgOTf promoter system,[30,44,49–52] which generates *p*-TolSOTf *in situ*. *p*-TolSOTf is a powerful thiophilic agent, capable of activating thioglycosides even with very low anomeric reactivities.[48,53,54] Moreover, the side product *p*-tolyl disulfide produced from pre-activation is not electrophilic, thus will not activate the thioglycoside acceptor. Alternatively, reagent combinations such as benzene sulfinyl piperidine/triflic anhydride (Tf₂O),[55] S-(4-methoxyphenyl) benzenethiosulfinate/Tf₂O,[56] benzene sulfinyl morpholine/Tf₂O,[57] and diphenylsulfoxide/Tf₂O[58] have also been used as thioglycoside promoters for pre-activation reactions. However, electrophilic side products are typically generated with these promoters, which often require the addition of a quencher such as triethyl phosphite at the end of the reaction to prevent undesired acceptor activation.[45,59] This renders it difficult to carry out multiple sequential glycosylations in the same reaction flask without intermediate purification.

Disaccharide donor **5** was prepared from disaccharide **8**[30] starting with treatment of sodium hydride and benzyl bromide. Reduction of the azide moiety and subsequent Troc protection produced the disaccharide donor **5** in 81% overall yield for the three steps (Scheme 1). Galactoside **6** and lactoside **7** were prepared according to literature.[30,60]

With all necessary building blocks in hand, we performed the assembly of SSEA-3 using the pre-activation based one-pot protocol.[30,44] With future automation in mind, we decided to carry out the one pot synthesis under the reaction condition established previously without optimization. Pre-activation of the disaccharide donor **5** at –78 °C with *p*-TolSCI/AgOTf was followed by the addition of the bifunctional building block **6** (Scheme 2a). A sterically hindered base, 2,4,6-tri-*tert*-butyl-pyrimidine (TTBP)[61] was added with **6** to neutralize triflic acid generated from glycosylation. The reaction temperature was raised to –20 °C to expedite glycosylation, and the acceptor **6** was completely consumed as judged by TLC analysis. The reaction temperature was cooled back down to –78°C, followed by addition of the lactoside acceptor **7** and *p*-TolSCI/AgOTf. The fully protected SSEA-3 pentasaccharide **4a** were obtained in 37% yield from this three component one-pot reaction sequence within six hours, which was fully characterized by ¹H-NMR, ¹³C-NMR, gCOSY, gHMQC and HRMS. In addition, the anomer **4b** was also separated in 13% yield. The presence or absence of the base TTBP did not significantly affect either the yield or the stereochemical selectivity of this reaction.[62]

Deprotection of the pentasaccharide **4a** was performed by first removing the Troc group with 1 M NaOH in THF followed by acetylation. Staudinger reduction of the azide group and subsequent catalytic hydrogenation over Pearlman's catalyst[30,50,51,63] gave the fully deprotected SSEA-3 **3** in 55% overall yield for all the deprotection steps (Scheme 2b).

Formation of the challenging Gal- α -1-4-Gal linkage, stereochemical dependence on donor

We examined next the stereochemical outcome in formation of the α -Gal-(1 $\rightarrow$ 4)-Gal linkage, which is a major challenge in syntheses of all globo series of gangliosides, with anomeric mixture of products often obtained.[28,60,64] We have reported that glycosylation of the lactoside acceptor **7** by the galactoside **9**[30] gave the Gb3 trisaccharide **10** in a combined 85% yield with an α : β ratio of 27:1 (Table 1, entry 1),[30] which compared favorably with literature results on Gb3 synthesis.[28,60,64] The large difference in stereochemical selectivity between Gb3 trisaccharide **10** and SSEA-3 pentasaccharide **4** prompted us to prepare the disaccharide donor **11**, the trisaccharide donor **12** and the tetrasaccharide donor **13** (Scheme 3). Pre-activation of donor **14**[30] by *p*-TolSCl/AgOTf followed by addition of the galactoside **6** generated the disaccharide **11** in 70% yield and the glycosylation of **6** by **5** produced the trisaccharide **12** (Scheme 3a,b). The successful glycosylation of armed galactoside **6** by the disarmed donor **14** is a salient feature of the pre-activation method. One pot sequential glycosylation of fucoside **15**,³⁰ disaccharide **16**³⁰ and galactoside **6** led to the tetrasaccharide donor **13** in 60% overall yield (Scheme 3c).

The glycosylation of lactoside **7** by donors **11**, **12** and **13** were then performed. The reaction of disaccharide donor **11** with **7** gave tetrasaccharides **17a** (71%) and **17b** (19%) (**17a**:**17b** = 3.7:1, Table 1, entry 2). Trisaccharide **12** glycosylated the lactoside **7** with an α : β ratio of 2.6 (Table 1, entry 3), which was similar to that obtained in one-pot synthesis of SSEA-3 (Scheme 2) indicating that one-pot procedure did not significantly affect the stereoselectivity. A further reduction in α : β selectivity (1.9:1) was observed in glycosylation of **7** by the tetrasaccharide donor **13** (Table 1, entry 4). These results suggested that as the glycosyl donor became larger, the α selectivity became lower although the overall yields were similar. The stereoselectivity change must be reflective of the rate differential of axial versus equatorial approach of the nucleophile onto the reactive intermediate(s),[51,65] because no anomeric bond isomerizations were observed when the *O*-glycoside products were re-submitted to the glycosylation reaction condition.

It is possible that the stereochemical divergence in glycosylating the acceptor **7** may be attributed to changes in electronic properties and/or steric encumbrance of the glycosyl donors. The introduction of a single electron withdrawing group on glycosyl donors can greatly influence the stereoselectivity.[66,67] Inductively, the glycosyl units on 3-*O* of the reducing end galactose in donors **11–13** can be viewed as electron withdrawing groups.[51,68] Therefore we prepared donor **19** bearing a highly electron withdrawing *p*-nitrobenzoyl (*p*-NO₂Bz) moiety on its 3-*O* position through nitrobenzoylation of galactoside **6**. Glycosylation of the lactoside **7** by the donor **19** produced the trisaccharide **20α** in 78% yield with no corresponding β anomer isolated (Table 1, entry 5). This suggests that electronic properties of the donors do not play a major role in determining stereoselectivity in this case.

Crich and coworkers have reported that the presence of *tert*butyl-dimethyl silyl (TBDMS) group on 3-*O* of the mannosyl donor **21** led to significant decrease in β mannoside formation compared to the corresponding reaction with the benzyl bearing donor **22**. [69] This was rationalized by a steric buttressing effect as the bulky 3-*O* TBDMS moiety pushes the axial 2-*O* benzyl group towards the β face of the anomeric center, 1,2-*cis* (β mannosyl) glycosylation is hindered. Similar phenomena have been observed in modular synthesis of alternating β-(1→3)-β-(1→4) mannans,[70] where increased steric size on 3-*O* position of the donor in the form of another glycosyl unit reduced the amount of β mannoside product drastically. It is possible in our studies, the glycosyl units on the 3-*O* of reducing end galactose of donors **11**, **12** and **13** present a steric buttressing effect, pushing the equatorial 2-*O* benzyl towards the anomeric center, thus reducing the amount of 1,2-*cis* (α galactosyl) products. As the size of

the donor increases from monosaccharide **9** to tetrasaccharide **13**, the effect of the steric buttressing effect becomes greater resulting in lower α selectivity.

Enzymatic synthesis of Globo-H **1a** and MSGG **2a**

Fucosylation of the SSEA-3 pentasaccharide **3** was carried out using WbsJ[71] with GDP-fucose. Despite the presence of three galactosyl units in SSEA-3, the 2-OH of the non-reducing terminal galactose was selectively fucosylated leading to Globo-H **1a** in 71% yield (Scheme 4a), the identity of which was confirmed by NMR comparison with the Globo-H **1a** assembled via chemical synthesis.[30]

Sialylation of pentasaccharide **3** was performed with the *Campylobacter jejuni* Cst-I sialyltransferase (construct CST-06), which cleanly transformed SSEA-3 into SSEA-4 **2b** with 1.5 eq of CMP-Neu5Ac (Scheme 4a). The conversion was quantitative based on TLC but the isolated yield was 34%. Presumably, some product was lost during the workup and purification processes. SSEA-3 can also be sialylated by a multifunctional *Pasteurella multocida* sialyltransferase PmST1[72] to form SSEA-4 **2b** in over 90% yield based on TLC analysis. In addition, we found that SSEA-3 is a substrate for a recombinant *Photobacterium damsela* α 2,6-sialyltransferase Pd2,6ST[73] with a yield of 40% by TLC. These results indicate that the large size of the pentasaccharide acceptor **3** does not present an obstacle to these enzymatic glycosylation reactions.

As we have obtained the tetrasaccharide **17a**, we investigated whether its fully deprotected form can also serve as an enzyme substrate. **17a** was deprotected in the same manner as described for the pentasaccharide **3**, producing the tetrasaccharide **23** in 50% yield (Scheme 4b). Tetrasaccharide **23** can serve as a substrate to galactosyl transferase LgtD,[41,74] providing an alternative access to SSEA-3.

In conclusion, we report the first chemoenzymatic syntheses of two tumor-associated carbohydrate antigens, Globo-H hexasaccharide **1b** and SSEA-4 hexasaccharide **2b**. The common precursor SSEA-3 pentasaccharide for these two compounds was assembled rapidly using the pre-activation based one-pot method. Enzymatic glycosylations of SSEA-3 by fucosyltransferase WbsJ and sialyltransferases CST-I or PmST1 led to Globo-H and SSEA-4 respectively. Interestingly, we observed that the stereoselectivities in formation of the challenging α -Gal-(1 $\rightarrow$ 4)-Gal linkage decreased when larger oligosaccharide donors were used. This was rationalized by a steric buttressing effect due to the glycosyl unit(s) linked to 3-O of the reducing end galactose in the donor.

Experimental Section

Characterization of anomeric stereochemistry

The stereochemistries of the newly formed glycosidic linkages in oligosaccharides are determined by $^3J_{H1,H2}$ through 1H -NMR and/or $^1J_{C1,H1}$ through gHMQC 2-D NMR (without 1H decoupling). Smaller coupling constants of $^3J_{H1,H2}$ (around 3 Hz) indicate 1,2-cis α linkages and larger coupling constants $^3J_{H1,H2}$ (7.2 Hz or larger) indicate 1,2-trans β linkages. This can be further confirmed by $^1J_{C1,H1}$ (~170 Hz) for α linkages and $^1J_{C1,H1}$ (~160 Hz) for β linkages.[75]

General procedure for single step pre-activation based glycosylation

A solution of donor (0.060 mmol) and freshly activated molecular sieve MS 4 Å (200 mg) in CH₂Cl₂ (2 mL) was stirred at room temperature for 30 minutes, and cooled to –78 °C, which was followed by addition of AgOTf (47 mg, 0.18 mmol) dissolved in Et₂O (1 mL) without touching the wall of the flask. After 5 minutes, orange colored *p*-TolSCl (9.5 µL, 0.060 mmol) was added through a microsyringe. Since the reaction temperature was lower than the freezing point of *p*-TolSCl, *p*-TolSCl was added directly into the reaction mixture to prevent it from freezing on the flask wall. The characteristic yellow color of *p*-TolSCl in the reaction solution dissipated rapidly within a few seconds indicating depletion of *p*-TolSCl. After the donor was completely consumed according to TLC analysis (about 5 minutes at –78 °C), a solution of acceptor (0.060 mmol) in CH₂Cl₂ (0.2 mL) was slowly added dropwise via a syringe. The reaction mixture was warmed to –20 °C under stirring in 2 hours. Then the mixture was diluted with CH₂Cl₂ (20 mL) and filtered over Celite. The Celite was further washed with CH₂Cl₂ until no organic compounds were observed in the filtrate by TLC. All CH₂Cl₂ solutions were combined and washed twice with saturated aqueous solution of NaHCO₃ (20 mL) and twice with water (10 mL). The organic layer was collected and dried over Na₂SO₄. After removal of the solvent, the desired disaccharide was purified from the reaction mixture via silica gel flash chromatography.

***p*-Tolyl 2,3,4,6-tetra-*O*-benzyl-β-D-galactopyranosyl-(1→3)-4,6-benzylidene-2-(2,2,2-tri-chloroethoxycarbonylamino)-2-deoxy-1-thio-β-D-galactopyranoside (5)**

Galactoside **8**[30] (0.4 g, 0.48 mmol) was dissolved in DMF (10 mL) and the solution was cooled to 0 °C. NaH (0.029 g, 60% NaH in mineral oil, 0.72 mmol) was added in portions, followed by addition of benzyl bromide (0.086 mL, 0.72 mmol). The mixture was stirred at room temperature under N₂ for 2 h and then diluted with EtOAc (50 mL). The mixture was washed with saturated NaHCO₃, water and then dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded *p*-tolyl 2,3,4,6-tetra-*O*-benzyl-β-D-galactopyranosyl-(1→3)-2-azido-4,6-benzylidene-2-deoxy-1-thio-β-D-galactopyranoside **S1** as white solid (0.44 g, quantitative); **S1** (0.44 g, 0.48 mmol), 1,3-propanedithiol (0.48 mL, 4.8 mmol) and Et₃N (0.67 mL, 4.8 mmol) were dissolved in a mixture of CH₂Cl₂/MeOH (5 mL each). The mixture was heated at reflux overnight under N₂ and then concentrated. The resulting residue was diluted with CH₂Cl₂ (60 mL) and then washed with saturated aqueous solution of NaHCO₃ and water, dried over Na₂SO₄, filtered and concentrated. The resulting residue was purified by quickly passing through a short silica gel column (20:1, CH₂Cl₂–MeOH) and the obtained solid and solid NaHCO₃ (0.078 g, 0.93 mmol) were put into THF (5 mL) and then TrocCl (0.075 mL, 0.56 mmol) was added. The mixture was stirred at room temperature under N₂ for 4 hours and filtrated. The filtrate was concentrated and then diluted with CH₂Cl₂ (50 mL). The mixture was washed with water and brine, dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded compound **5** as white solid (0.42 g, 81% for two steps).

3-Azidopropyl 2,3,4,6-tetra-*O*-benzyl-β-D-galactopyranosyl-(1→3)-4,6-benzylidene-2-(2,2,2-tri-chloroethoxycarbonylamino)-2-deoxy-β-D-galactopyranosyl-(1→3)-2,4,6-tri-*O*-benzyl-α-D-galactopyranosyl-(1→4)-2,3,6-tri-*O*-benzyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-*O*-benzyl-β-D-glucopyranoside (4α) and 3-azidopropyl 2,3,4,6-tetra-*O*-benzyl-β-D-galactopyranosyl-(1→3)-4,6-benzylidene-2-(2,2,2-tri-chloroethoxycarbonylamino)-2-deoxy-β-D-galactopyranosyl-(1→3)-2,4,6-tri-*O*-benzyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-*O*-benzyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-*O*-benzyl-β-D-glucopyranoside (4β)

After donor **5** (50 mg, 46.7 µmol) and activated molecular sieve MS-4 Å (500 mg) were stirred for 30 minutes at room temperature in CH₂Cl₂ (3 mL), the solution was cooled to –78 °C, followed by addition of AgOTf (36 mg, 140 µmol) in Et₂O (1.5 mL). The mixture was stirred

for 5 minutes at -78°C and then *p*-TolSCl (7.4 μL , 46.7 μmol) was added into the solution. (See the general procedure for single step pre-activation based glycosylation for precautions) The mixture was vigorously stirred for 10 minutes, followed by addition of a solution of acceptor **6** (22.1 mg, 39.7 μmol) and TTBP (6.9 mg, 46.7 μmol) in CH_2Cl_2 (1 mL). The reaction mixture was stirred for 2 hours from -78 to -20°C and then the mixture was cooled down to -78°C , followed by sequential additions of AgOTf (12 mg, 46.7 μmol) in Et_2O (1 mL), acceptor **7** (22.5 mg, 23.3 μmol) and TTBP (6.9 mg, 46.7 μmol) in CH_2Cl_2 (1 mL). The mixture was stirred for 5 minutes at -78°C and then *p*-TolSCl (6.3 μL , 39.7 μmol) was added into the solution. The reaction mixture was stirred for 3 hours from -78 to 10°C and then was quenched with Et_3N (40 μL), concentrated under vacuum to dryness. The resulting residue was diluted with CH_2Cl_2 (30 mL), followed by filtration. The organic phase was washed with saturated aqueous NaHCO_3 , H_2O and then dried over Na_2SO_4 , filtered and concentrated. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded 20 mg of **4a** (37%) and 7.2 mg of **4b** (13%) respectively as colorless gel.

Compounds **4a** and **4b** were also synthesized from donor **12** and acceptor **7** in 60% and 23% yield respectively as colorless gel following the general procedure of single step glycosylation.

3-Aminopropyl β -D-galactopyranosyl-(1 $\rightarrow$ 3)-2-acetamido-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)- α -D-galactopyranosyl-(1 $\rightarrow$ 4)- β -D-galactopyranosyl-(1 $\rightarrow$ 4)- β -D-glucopyranoside (3**)**

The mixture of compound **4a** (60 mg, 25.5 μmol), 1 M NaOH (4 mL, 0.4 mmol) and THF (4 mL) was stirred at 50°C overnight and then concentrated to dryness. The resulting residue was diluted with CH_2Cl_2 (30 mL) and the organic phase was washed by H_2O and then dried over Na_2SO_4 , filtered and concentrated to dryness. The resulting residue was dissolved in methanol (2 mL) and acetic anhydride (24 μL , 0.25 mmol) was added dropwise and the mixture was stirred at room temperature under N_2 overnight. The reaction was quenched by adding a few drops of H_2O and then diluted with CH_2Cl_2 (30 mL). The organic phase was washed with saturated aqueous solution of NaHCO_3 , H_2O and then dried over Na_2SO_4 , filtered and concentrated to dryness. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded the *N*-acetylation product as white solid. The mixture of the *N*-acetylation product, 1 M of PMe_3 in THF (0.5 mL, 0.5 mmol), 0.1 M NaOH (0.5 mL, 0.05 mmol) and THF (4 mL) was stirred at 60°C under N_2 overnight. The mixture was concentrated and the resulting residue was diluted with CH_2Cl_2 (30 mL). The organic phase was washed with H_2O and then dried over Na_2SO_4 , filtered and concentrated to dryness. The resulting residue was purified by quickly passing through a short silica gel column (10:1, CH_2Cl_2 –MeOH). The mixture of the obtained solid and $\text{Pd}(\text{OH})_2$ in MeOH/ H_2O /HOAc (3 mL/1 mL/1 mL) was stirred under H_2 at room temperature overnight and then filtered. The filtrate was concentrated to dryness under vacuum and then was co-evaporated with H_2O (10 mL) three times to remove the HOAc. The aqueous phase was further washed with CH_2Cl_2 (5 mL $\times$ 3) and EtOAc (5 mL $\times$ 3) and then the aqueous phase was dried under vacuum to afford compound **3** (acetate salt) as white solid (13 mg, 55% for four steps).

***p*-Tolyl 3,4,6-tri-*O*-acetyl-2-(2,2,2-tri-chloroethoxycarbonylamino)-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-2,4,6-tri-*O*-benzyl-1-thio- β -D-galactopyranoside (**11**)**

Compound **11** was synthesized from donor **14** and acceptor **6** in 70% yield following the general procedure of glycosylation.

***p*-Tolyl 2,3,4,6-tetra-*O*-benzyl- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-4,6-benzylidene-2-(2,2,2-tri-chloroethoxycarbonylamino)-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-2,4,6-tri-*O*-benzyl-1-thio- β -D-galactopyranoside (**12**)**

Compound **12** was synthesized from donor **5** and acceptor **6** in 71% yield following the general procedure of single step glycosylation.

3-Azidopropyl 2,3,4-tri-*O*-benzyl- α -L-fucopyranosyl-(1 $\rightarrow$ 2)-3,4,6-tri-*O*-benzyl- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-4,6-benzylidene-2-(2,2,2-trichloroethoxycarbonylamino)-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-2,4,6-tri-*O*-benzyl-1-thio- β -D-galactopyranoside (13)

Compound **13** was synthesized by a three component one-pot synthesis procedure. After the donor *p*-tolyl 2,3,4-tri-*O*-benzyl-1-thio- β -L-fucopyranoside **15** [30] (50 mg, 92.47 μ mol) and activated molecular sieve MS-4 Å (500 mg) were stirred for 30 minutes at room temperature in Et₂O (4 mL), the solution was cooled to -78°C , followed by addition of AgOTf (72 mg, 277.4 μ mol) in Et₂O (1.5 mL). The mixture was stirred for 5 minutes at -78°C and then *p*-TolSCI (14.7 μ L, 92.47 μ mol) was added into the solution. (See the general procedure for single step pre-activation based glycosylation for precautions) The mixture was vigorously stirred for 10 minutes, followed by addition of a solution of acceptor *p*-tolyl 3,4,6-tri-*O*-benzyl- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-4,6-benzylidene-2-(2,2,2-trichloroethoxycarbonylamino)-2-deoxy-1-thio- β -D-galactopyranoside **16**[30] (77.1 mg, 78.60 μ mol) and TTBP (23 mg, 92.47 μ mol) in CH₂Cl₂ (1 mL). The reaction mixture was stirred for 2 hours from -78°C to -20°C and then the mixture was cooled down to -78°C , followed by addition of AgOTf (24 mg, 92.47 μ mol) in Et₂O (1 mL). The mixture was stirred for 10 minutes at -78°C and then *p*-TolSCI (12.5 μ L, 78.60 μ mol) was added into the solution. After stirred for 5 minutes, a solution of acceptor **6** (30.9 mg, 55.48 μ mol) and TTBP (23 mg, 92.47 μ mol) in CH₂Cl₂ (1 mL) was added slowly along the flask wall into the mixture and the reaction mixture was stirred for 2 h from -78°C to -20°C and then reaction was quenched with Et₃N (40 μ L), concentrated under vacuum to dryness. The resulting residue was diluted with CH₂Cl₂ (30 mL), followed by filtration. The organic phase was washed with saturated aqueous NaHCO₃, H₂O and then dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded **13** as colorless gel (60.6 mg, 60 %).

3-Azidopropyl 3,4,6-tri-*O*-acetyl-2-(2,2,2-trichloroethoxycarbonylamino)-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-2,4,6-tri-*O*-benzyl- α -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-*O*-benzyl- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-2,4,6-tri-*O*-benzyl- β -D-glucopyranoside (17 α) and 3-azidopropyl 3,4,6-tri-*O*-acetyl-2-(2,2,2-trichloroethoxycarbonylamino)-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-2,4,6-tri-*O*-benzyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-*O*-benzyl- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-2,4,6-tri-*O*-benzyl- β -D-glucopyranoside (17 β)

Compound **17 α** and **17 β** were synthesized from donor **11** and acceptor **7** in 71% and 19% yield respectively as colorless gel following the general procedure of single step glycosylation.

3-Azidopropyl 2,3,4-tri-*O*-benzyl- α -L-fucopyranosyl-(1 $\rightarrow$ 2)-3,4,6-tri-*O*-benzyl- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-4,6-benzylidene-2-(2,2,2-trichloroethoxycarbonylamino)-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-2,4,6-tri-*O*-benzyl- α -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-*O*-benzyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-*O*-benzyl- β -D-glucopyranoside (18 α) and 3-azidopropyl 2,3,4-tri-*O*-benzyl- α -L-fucopyranosyl-(1 $\rightarrow$ 2)-3,4,6-tri-*O*-benzyl- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-4,6-benzylidene-2-(2,2,2-trichloroethoxycarbonylamino)-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-2,4,6-tri-*O*-benzyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-*O*-benzyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-*O*-benzyl- β -D-glucopyranoside (18 β)

Compound **18 α** and **18 β** were synthesized from donor **13** and acceptor **7** in 57% and 30% yield respectively as colorless gel following the general procedure of single step glycosylation. The identities of which were confirmed by NMR comparison with literature data.[30]

***p*-Tolyl 2,4,6-tri-*O*-benzyl-3-*O*-*p*-nitrobenzoyl-1-thio- β -D-galactopyranoside (19)**

Compound **6** (43.5 mg, 0.078 mmol) and *N,N*-dimethylamino pyridine (9.5 mg, 0.078 mmol) was dissolved in CH₂Cl₂ (5 mL), followed by the addition of *p*-nitrobenzoyl chloride (10.9 μ L, 0.09 mmol). The mixture was stirred overnight at room temperature and then diluted with CH₂Cl₂ (20 mL), washed with saturated aqueous NaHCO₃ and H₂O and then dried over

Na₂SO₄, filtered and concentrated. Silica gel column chromatography (4:1 Hexanes–EtOAc) afforded **19** as gel-like solid (50.6 mg, 92%).

3-Azidopropyl 2,4,6-tri-O-benzyl-3-O-p-nitrobenzoyl- α -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-benzyl- β -D-galactopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-benzyl- β -D-glucopyranoside (20a)

After donor **19** (30 mg, 42 μ mol), acceptor **7** (37 mg, 38 μ mol) and activated molecular sieve MS-4 Å (200 mg) were stirred for 30 min at room temperature in a mixture solvent of Et₂O (1 mL) and CH₂Cl₂ (2 mL), the mixture was cooled to – 78 °C, followed by addition of AgOTf (33 mg, 0.127 mmol) in Et₂O (1 mL). The mixture was vigorously stirred for 10 min and then *p*-TolSCl (6.74 μ L, 42 μ mol) was added and the reaction mixture was stirred for 2 h from – 78 to – 20 °C. The reaction was quenched by Et₃N and then concentrated under vacuum to dryness. The resulting residue was diluted with CH₂Cl₂ (10 mL), followed by filtration. The organic phase was washed with saturated aqueous NaHCO₃ and H₂O and then dried over Na₂SO₄, filtered and concentrated. Silica gel column chromatography (3:1 Hexanes–EtOAc) afforded **20a** as gel-like solid (46.2 mg, 78%).

3-Aminopropyl α -L-fucopyranosyl-(1 $\rightarrow$ 2)- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-2-acetamido-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)- α -D-galactopyranosyl-(1 $\rightarrow$ 4)- β -D-galactopyranosyl-(1 $\rightarrow$ 4)- β -D-glucopyranoside (1b)

To a mixture of 10 mM SSEA-3 pentasaccharide **3**, 15 mM GDP-fucose in 20 mM Tris-HCl buffer (pH 7.5) was added α 1,2 fucosyltransferase WbsJ (7 mU). The mixture was incubated at room temperature for 2 days. The Globo-H hexasaccharide **1b** was purified by BioGel P-2 gel filtration column (BioRad) followed by Dowex 1x8-400 ion exchange resin (Chloride form) with water as the mobile phase. The fractions containing the desired product **1b** (71%) was collected and lyophilized. NMR data of **1b** were collected, which were identical to those obtained from Globo-H **1b** synthesized chemically.[30]

3-Aminopropyl 5-acetamido-3,5-dideoxy-D-glycero- α -D-galacto-non-2-ulopyranosylonic acid-(2 $\rightarrow$ 3)- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-2-acetamido-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)- α -D-galactopyranosyl-(1 $\rightarrow$ 4)- β -D-galactopyranosyl-(1 $\rightarrow$ 4)- β -D-glucopyranoside (2b)

The *Campylobacter jejuni* CST-I α -2,3-sialyltransferase (construct CST-06) was expressed as a fusion protein with the *E. coli* maltose-binding protein and purified.[39] To a mixture of 10 mM MgCl₂, 5 mM SSEA-3 pentasaccharide **3**, 7.5 mM CMP-Neu5Ac in Hepes buffer (50 mM, pH 7.5) was added CST-I α -2,3-sialyltransferase (0.32 U/mL). The reaction was incubated at 37°C for 2 h and TLC (BPH:AMW = 1:1, BPH 1:2:1 *n*butanol: propanol: 0.1 M HCl; AMW 1:1:1 CH₃CN: methanol: water) showed complete consumption of the pentasaccharide **3**. Multiple reactions were set to convert all of the pentasaccharide **3** (9 mg, 9.1 μ mol). The reaction volume was reduced using a centrifugal concentrator and the material was loaded (in 3 runs) on a 10 mm $\times$ 30 cm Superdex Peptide column (GE Healthcare). The column was eluted with an ammonium acetate buffer (pH 7, 20 mM) at 0.5 mL/min. The product was eluted between 7 and 8 mL. The fractions were pooled and lyophilized three times to remove the ammonium acetate. We recovered 4 mg (3.1 μ mol) of purified **2b** with a yield of 34%. As the conditions for enzymatic synthesis were very mild and previously we did not observe any product decomposition using this enzyme,[39] the low isolated yield was probably due to multiple small scale reactions performed resulting in loss of product during workup and purification.

Enzymatic sialylation of pentasaccharide SSEA-3 using PmST1 and Pd2,6ST

The enzymatic assays were carried out in a total volume of 10 μ L in a Tris-HCl buffer (100 mM, pH 8.5) containing CMP-Neu5Ac (20 mM), SSEA-3 **3** (10 mM), MgCl₂ (20 mM) and the corresponding sialyltransferases (PmST1 or Pd2,6ST). Reactions were allowed to proceed

for 60 min at 37 °C. The reactions were then monitored by TLC (BPH: AMW= 1:1) and the products formed were confirmed by MS. ESI-MS for sialylation product catalysed by PmST1: $[M+Na]^+$ $C_{46}H_{78}N_3Na_2O_{34}$ calcd 1262.43, obsd 1262.29; ESI-MS for sialylation product catalysed by Pd2,6ST: $[M+Na]^+$ $C_{46}H_{78}N_3Na_2O_{34}$ calcd 1262.43, obsd 1262.28.

3-Aminopropyl 2-acetamido-2-deoxy- β -D-galactopyranosyl-(1 $\rightarrow$ 3)- α -D-galactopyranosyl-(1 $\rightarrow$ 4)- β -D-galactopyranosyl-(1 $\rightarrow$ 4)- β -D-glucopyranoside (**23**)

The mixture of compound **17a** (0.050 g, 0.027 mmol), 1 M NaOMe (4.0 mL, 4.0 mmol) and THF (4 mL) was stirred at 50 °C overnight and then concentrated to dryness. The resulting residue was diluted with CH_2Cl_2 (50 mL) and the organic phase was washed by H_2O and then dried over Na_2SO_4 , filtered and concentrated to dryness. The resulting residue was dissolved in methanol (3 mL). Acetic anhydride (1.0 mL) was added dropwise and the mixture was stirred at room temperature under N_2 for 6 hours. The reaction was quenched by adding EtOH and then diluted with EtOAc (20 mL). The organic phase was washed with saturated aqueous solution of $NaHCO_3$, H_2O and then dried over Na_2SO_4 , filtered and concentrated to dryness. Silica gel column chromatography (2:1 Hexanes–EtOAc) afforded the *N*-acetylation product as white solid. The mixture of the *N*-acetylation product, 1 M of PMe_3 in THF (0.5 mL, 0.5 mmol) and THF (3 mL) was stirred at 50 °C under N_2 overnight. The mixture was concentrated and the resulting residue was diluted with CH_2Cl_2 (50 mL). The organic phase was washed with H_2O and then dried over Na_2SO_4 , filtered and concentrated to dryness. The resulting residue was purified by quickly passing through a short silica gel column (10:1, CH_2Cl_2 –MeOH). The mixture of the obtained solid and $Pd(OH)_2$ in MeOH/ H_2O /HOAc (5 mL, 3:1:1) was stirred under H_2 at room temperature overnight and then filtered. The filtrate was concentrated to dryness under vacuum and then was co-evaporated with H_2O (10 mL) three times to remove the HOAc. The aqueous phase was further washed with CH_2Cl_2 (5 mL $\times$ 3) and EtOAc (5 mL $\times$ 3) and then the aqueous phase was dried under vacuum to afford compound **23** as white solid (10.4 mg, 50% for three steps).

Enzymatic galactosylation of tetrasaccharide **23**

To a mixture of 10 mM tetrasaccharide **23**, 20 mM UDP-galactose, 1 mM $MnCl_2$, 1 mM dithiothreitol and 1 % BSA in 20 mM Tris-HCl buffer (pH 7.5) was added β 1,3 galactosyltransferase (LgtD) (2 mU). The mixture was incubated at room temperature for 2 days. The SSEA-3 penta-saccharide **3** (70%) was purified by BioGel P-2 gel filtration column (BioRad) followed by Dowex 1x8-400 ion exchange resin (chloride form) with water as the mobile phase.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are grateful for financial supports from the National Institutes of Health (R01-GM-72667 to XH, R01GM076360 to XC). We would like to thank Dr. Warren Wakarchuk (National Research Council Canada) for helpful suggestions, Dr. Jianjun Li (National Research Council Canada) for mass spectrometry analysis of the sialylated product and Marie-France Karwaski (National Research Council Canada) for technical help.

References

1. Ishida H, Kiso M. Trends Glycosci Glycotech 2001;13:57–64.
2. Hakomori S, Zhang Y. Chem Biol 1997;4:97–104. [PubMed: 9190292]
3. Wedeking A, van Echten-Deckert G. Curr Org Chem 2007;11:579–598.
4. Izumi M, Uzawa H. Trends Glycosci Glycotech 2005;17:107–119.

5. Birkle S, Zeng G, Gao L, Yu RK, Aubry J. *Biochimie* 2003;85:455–463. [PubMed: 12770784]
6. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. *Clin Cancer Res* 1998;4:295–302. [PubMed: 9516914]
7. Bremer EG, Levery SB, Sonnino S, Ghidoni R, Canevari S, Kannagi R, Hakomori S. *J Biol Chem* 1984;259:14773–14777. [PubMed: 6501317]
8. Danishefsky SJ, Allen JR. *Angew Chem Int Ed* 2000;39:836–863.
9. Gilewske T, Ragupathi G, Bhuta S, Williams LJ, Musselli C, Zhang XF, Bencsath KP, Panageas KS, Chin J, Hudis CA, Norton L, Houghton AN, Livingston PO, Danishefsky SJ. *Proc Natl Acad Sci U S A* 2001;98:3270–3275. [PubMed: 11248068]
10. Wang ZG, Williams LJ, Zhang XF, Zatorski A, Kudrya-shov V, Ragupathi G, Spassova M, Bornmann W, Slovin SF, Scher HI, Livingston PO, Lloyd KO, Danishefsky SJ. *Proc Natl Acad Sci U S A* 2000;97:2719. [PubMed: 10716997]
11. Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, Spassova M, Bornmann WG, Fazzari M, Dantis L, Olkiewicz K, Lloyd KO, Livingston PO, Danishefsky SJ, Scher HI. *Proc Natl Acad Sci U S A* 1999;96:5710. [PubMed: 10318949]
12. Stapleton AE, Stroud MR, Hakomori SI, Stamm WE. *Infect Immun* 1998;66:3856–3861. [PubMed: 9673272]
13. Stroud MR, Stapleton AE, Levery SB. *Biochem* 1998;37:17420–17428. [PubMed: 9860857]
14. Stapleton A, Nudelman E, Clausen H, Hakomori S, Stamm WE. *J Clin Invest* 1992;90:965–972. [PubMed: 1522244]
15. Cooling LLW, Koerner TAW, Naides SJ. *J Infect Dis* 1995;172:1198–1205. [PubMed: 7594654]
16. Katagiri YU, Ohmi K, Katagiri C, Sekino T, Nakajima H, Ebata T, Kiyokawa N, Fujimoto J. *Glycoconjugate J* 2001;18:347–353.
17. Wenk J, Andrews PW, Casper J, Hata J, Pera MF, von Keitz A, Damjanov I, Fenderson BA. *Int J Cancer* 1994;58:108–115. [PubMed: 8014006]
18. Krupnick JG, Damjanov I, Damjanov A, Zhu ZM, Fenderson BA. *Int J Cancer* 1994;59:692–698. [PubMed: 7960243]
19. Kannagi R, Levery SB, Ishigami F, Hakomori S, Shevinsky LH, Knowles BB, Solter D. *J Biol Chem* 1983;258:8934–8942. [PubMed: 6863318]
20. Saito S, Aoki H, Ito A, Ueno S, Wada T, Mitsuzuka K, Satoh M, Arai Y, Miyagi T. *J Biol Chem* 2003;278:26474–26479. [PubMed: 12716912]
21. Steelant WF, Kawakami Y, Ito A, Handa K, Bruyneel EA, Mareel M, Hakomori S. *FEBS Lett* 2002;531:93–98. [PubMed: 12401210]
22. Saito S, Orikasa S, Satoh M, Ohyama C, Ito A, Takahashi T. *Jpn J Cancer Res* 1997;88:652–659. [PubMed: 9310138]
23. Saito S, Orikasa S, Ohyama C, Satoh M, Fukushi Y. *Int J Cancer* 1991;49:329–334. [PubMed: 1917130]
24. Kiso, M.; Ishida, H.; Hiromne, A. *Carbohydrate-Based Drug Discovery*. Wong, C-H., editor. Vol. 1. Wiley-VCH; Weinheim: 2003. p. 37–54.
25. Allen JR, Allen JG, Zhang XF, Williams LJ, Zatorski A, Ragupathi G, Livingston PO, Danishefsky SJ. *Chem Eur J* 2000;6:1366–1375.
26. Lassaletta JM, Schmidt RR. *Liebigs Ann Chem* 1996:1417–1423.
27. Zhu T, Boons GJ. *Angew Chem Int Ed* 1999;38:3495–3497.
28. Werz DD, Castagner B, Seeberger PH. *J Am Chem Soc* 2007;129:2770–2771. [PubMed: 17302423]
29. Huang CY, Thayer DA, Chang AY, Best M, Hoffmann L, Head S, Wong CH. *Proc Natl Acad Sci U S A* 2006;100:15–20. [PubMed: 16373501]
30. Wang Z, Zhou L, El-boubbou K, Ye X-S, Huang X. *J Org Chem* 2007;72:6409–6420. [PubMed: 17658849]
31. Crich D, Wu B. *Tetrahedron* 2008;64:2042–2047. and references cited therein. [PubMed: 19247426]
32. Boons GJ, Demchenko A. *Chem Rev* 2000;100:4539–4565. [PubMed: 11749357]
33. Seifert J, Lergenmuller M, Ito Y. *Angew Chem Int Ed* 2000;39:531–534.
34. Ishida H, Miyawaki R, Kiso M, Hasegawa A. *J Carbohydr Chem* 1996;15:163–182.

35. Lassaletta JM, Carlsson K, Garegg PJ, Schmidt RR. *J Org Chem* 1996;61:6873–6880. [PubMed: 11667581]
36. Koeller KM, Wong CH. *Chem Rev* 2000;100:4465–4493. and references cited therein. [PubMed: 11749355]
37. Wymer N, Toone EJ. *Curr Opin Chem Biol* 2000;4:110–119. [PubMed: 10679369]
38. Duclos RI. *Carbohydr Res* 2000;328:489–507. [PubMed: 11093705]
39. Blixt O, Vasiliu D, Allin K, Jacobsen N, Warnock D, Razi N, Paulson JC, Bernatchez S, Gilbert M, Wakarchuk W. *Carbohydr Res* 2005;340:1963–1972. [PubMed: 16005859]
40. Kamath VP, Yeske RE, Gregson JM, Ratcliffe RM, Fang YR, Palcic MM. *Carbohydr Res* 2004;339:1141–1146. and references cited therein. [PubMed: 15063203]
41. Randrianitsoa M, Drouillard S, Breton C, Samain E. *FEBS Lett* 2007;581:2652–2656. [PubMed: 17517393]
42. Kannagi R, Cochran NA, Ishigami F, Hakomori S, Andrews PW, Knowles BB, Solter D. *EMBO J* 1983;2:2355–2361. [PubMed: 6141938]
43. Mootoo DR, Konradsson P, Udodong U, Fraser-Reid B. *J Am Chem Soc* 1988;110:5583–5584.
44. Huang X, Huang L, Wang H, Ye XS. *Angew Chem Int Ed* 2004;42:5221–5224.
45. Codee JDC, van den Bos LJ, Litjens REJN, Overkleef HS, van Boeckel CAA, van Boom JH, van der Marel GA. *Tetrahedron* 2004;60:1057–1064.
46. Yamago S, Yamada T, Maruyama T, Yoshida JI. *Angew Chem Int Ed* 2004;43:2145–2148.
47. Nguyen HM, Poole JL, Gin DY. *Angew Chem Int Ed* 2001;40:414–417.
48. Crich D, Sun S. *Tetrahedron* 1998;54:8321–8348.
49. Huang L, Huang X. *Chem Eur J* 2007;13:529–540.
50. Miermont A, Zeng Y, Jing Y, Ye XS, Huang X. *J Org Chem* 2007;72:8958–8961. [PubMed: 17939723]
51. Teumelsan N, Huang X. *J Org Chem* 2007;72:8976–8979. [PubMed: 17939719]
52. Huang L, Wang Z, Li X, Ye XS, Huang X. *Carbohydr Res* 2006;341:1669–1679. [PubMed: 16442505]
53. Huang L, Wang Z, Huang X. *Chem Commun* 2004;17:1960–1961.
54. Martichonok V, Whitesides GM. *J Org Chem* 1996;61:1702–1706. [PubMed: 11667039]
55. Crich D, Smith M. *J Am Chem Soc* 2001;123:9015–9020. [PubMed: 11552809]
56. Crich D, Smith M. *Org Lett* 2000;2:4067–4069. [PubMed: 11112645]
57. Wang C, Wang H, Huang X, Zhang LH, Ye XS. *Synlett* 2006:2846–2850.
58. Codee JDC, Litjens REJN, den Heeten R, Overkleef HS, van Boom JH, van der Marel GA. *Org Lett* 2003;5:1519–1522. [PubMed: 12713313]
59. Codee JDC, van den Bos LJ, Litjens REJN, Overkleef HS, van Boom JH, van der Marel GA. *Org Lett* 2003;5:1947–1950. [PubMed: 12762693]
60. Pornsuriyasak P, Demchenko AV. *Carbohydr Res* 2006;341:1458–1466. and references cited therein. [PubMed: 16643871]
61. Crich D, Smith M, Yao Q, Picione J. *Synthesis* 2001:323–326.
62. Gen Y, Zhang LH, Ye XS. *Chem Commun* 2008:597–599.
63. Li J, Wang J, Czyrca PG, Chang H, Orsak TW, Evanson R, Chang CWT. *Org Lett* 2004;6:1381–1384. [PubMed: 15101747]
64. Park TY, Kim JJ, Hu S, Bilodeau MT, Randolph JT, Kwon O, Danishefsky SJ. *J Am Chem Soc* 1996;118:11488–11500.
65. Garcia B, Gin DY. *J Am Chem Soc* 2000;122:4269–4279.
66. Abdel-Rahman AA-H, Jonke SJ, El Ashry ESH, Schmidt RR. *Angew Chem Int Ed* 2004;43:4389.
67. Crich D, Picione J. *Org Lett* 2003;5:781–784. [PubMed: 12605514]
68. Zhang Z, Ollman IR, Ye XS, Wischnat R, Baasov T, Wong CH. *J Am Chem Soc* 1999;121:734–753.
69. Crich D, Dudkin V. *Tetrahedron Lett* 2000;41:5643–5646.
70. Crich D, Li W, Li H. *J Am Chem Soc* 2004;126:15081–15086. [PubMed: 15548005]

71. Yi W, Shao J, Zhu L, Li M, Singh M, Lu Y, Lin S, Li H, Ryu K, Shen J, Guo H, Yao Q, Bush CA, Wang PG. *J Am Chem Soc* 2005;127:2040–2041. [PubMed: 15713070]
72. Yu H, Chokhawala H, Karpel H, Yu H, Wu B, Zhang J, Zhang Y, Jia Q, Chen X. *J Am Chem Soc* 2005;127:17618–17619. [PubMed: 16351087]
73. Yu H, Huang S, Chokhawala H, Sun M, Zheng H, Chen X. *Angew Chem Int Ed* 2005;45:3938–3944.
74. Su DM, Eguchi H, Yi W, Li L, Wang PG, Xia C. *Org Lett* 2008;10. in press.
75. Bock K, Pedersen C. *J Chem Soc Perkin Trans* 1974;2:293–297.

Figure 1.
Retrosynthetic analysis.

Scheme 1.

Scheme 2.

Scheme 3.

Scheme 4.

Table 1Evaluation of the formation of the α -Gal-(1 $\rightarrow$ 4)-Gal linkage

$\text{Donor(1 eq) + AgOTf} \xrightarrow[\text{Et}_2\text{O:CH}_2\text{Cl}_2]{p\text{-TolSCL, acceptor 7, } -78^\circ\text{C}} \text{Product}$			
Entry #	Donor	Product (Yield)	α/β
1	9	10 α (82%) + 10 β (3%)	27
2	11	17 α (71%) + 17 β (19%)	3.7
3	12	4 α (60%) + 4 β (23%)	2.6
4	13	18 α (57%) + 18 β (30%)	1.9
5	19	20 α (78%)	α only